LLY Stock Summary and Trading Ideas (Eli Lilly And Company | NYSE:LLY)

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Eli Lilly And Company trades on the NYSE stock market under the symbol LLY.

As of March 20, 2026, LLY stock price declined to $906.70 with 3,928,176 million shares trading.

LLY has a beta of 0.53, meaning it tends to be less sensitive to market movements. LLY has a correlation of 0.04 to the broad based SPY ETF.

LLY has a market cap of $809.68 billion. This is considered a Mega Cap stock.

Last quarter Eli Lilly And Company reported $19 billion in Revenue and $7.54 earnings per share. This beat revenue expectation by $1 billion and exceeded earnings estimates by $.58.

In the last 3 years, LLY traded as high as $1,133.95 and as low as $323.26.

The top ETF exchange traded funds that LLY belongs to (by Net Assets): VTI, VOO, VUG, IVV, SPY.

LLY has underperformed the market in the last year with a price return of +9.1% while the SPY ETF gained +15.6%. LLY has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -15.2% and -7.8%, respectively, while the SPY returned -4.7% and -4.8%, respectively.

LLY support price is $897.88 and resistance is $937.12 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LLY shares will trade within this expected range on the day.